GMMMG logo

NHS photos

NHS logo


<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during September 2016

October 2016


New Therapies Subgroup


The following New Therapies recommendations were signed off by GMMMG at their September meeting and are now available on the website. Please see links below for details around whether the drugs have been recommended for use or not:

Formulary Subgroup


The minutes from the September 2016 meeting are now available here

The FSG have made draft amendments to the formulary (October):

- the formulary will reflect TA401, TA402, TA403, TA404, TA405, TA406, TA407, TA408, TA409, TA410, TA411, TA412, CG42, CG141, CG126 and CG44 (including update in line with the recent NTS ulipristal for uterine fibroids recommendation.

The formulary will also reflect the Sept MHRA DSU with the addition of warnings for levonorgesterol-containing emergency contraceptive efficacy with hepatic enzyme inducers, posoconazole tablets vs oral suspension and idelalisib.

The group agreed by email in October that:

  • A link to the NTS ticagrelor recommendation, in addition to the NTS ulipristal recommendation, would be added to the formulary; both agents are already listed in formulary.
  • The formulary will be updated to reflect RAG recommendations approved by GMMMG in September

The following work is ongoing:

Development of a GM asthma pathway
GM anal irrigation systems pathway
Swollen leg guideline
RA pathway update
PsA/AS pathway update
IBD pathway
Pain pathway
Macular pathway
GM antibiotic guideline

Interface Prescribing


The following Shared Care Protocol has had some minor updates

It is also available as word document on the password protected part of the site under shared care.


Agenda for October 2016 meeting, plus the minutes of August 2016 meeting  of Interface Prescribing Subgroup have now been published and are available on site.



The next BGTS guidance review is postponed and subject to Drug Tariff update against ISO compliance (due to start in August 2017). New published evidence supporting additions or changes to existing evaluation can be submitted for review from July 2017. This information is captured in version 4.1 available on GMMMG website.  The expected document review date: autumn 2017.


A draft Botulinum policy [Consultation closed - link removed] is now available for consultation. This policy is intended for use within the Greater Manchester Health economy and we are seeking comments [Consultation closed - link removed] from all GM Healthcare Professionals. The closing date for comments is 5pm 11th November 2016.


A patient information leaflet on the use of omeprazole MUPS in paediatrics is available on the GMMMG website here.


The GMMMG Harmonised Biologics Pathway for Ankylosing Spondylitis and Psoriatic Arthritis has now been updated and is available on the pathways page of this website. It now also includes secukinumab following the release of NICE TA407 last week.

<< Back



RSS Feed